Sjögren's Syndrome Clinical Trials and Treatments

Sjögren's syndrome is driven by lymphocytic infiltration of exocrine glands, where T cells and B cells progressively destroy glandular tissue. The autoimmune process involves anti-SSA/Ro and anti-SSB/La autoantibodies (present in 60-70% and 30-50% of patients, respectively), which are useful diagnostic markers and can appear years before clinical symptoms. The condition extends well beyond dryness.

The most common symptoms of Sjögren's Syndrome include Severe dry mouth (xerostomia) causing difficulty swallowing, speaking, and increased dental decay, Persistent dry, gritty, or burning eyes (keratoconjunctivitis sicca), Debilitating fatigue that does not improve with rest, Joint pain and swelling, often mimicking rheumatoid arthritis, Swollen parotid (salivary) glands in the cheeks, among others. Estimated 1 to 4 million Americans (including undiagnosed); approximately 1 in 1,000 adults based on physician-diagnosed prevalence. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Sjögren's Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Sjögren's syndrome has no FDA-approved disease-modifying treatment, which means clinical trials represent a real opportunity for patients with moderate-to-severe disease who aren't adequately controlled with symptomatic therapies. Trials are testing B-cell depletion (ianalumab, which targets BAFF receptor), TYK2 inhibitors (deucravacitinib), T-cell co-stimulation blockers (dazodalibep), and dual BAFF/APRIL inhibitors (telitacicept).

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Sjögren's Syndrome: Evoxac (cevimeline), first approved in 2000; Salagen (pilocarpine), first approved in 1994; and Corticosteroids (prednisone, prednisolone). Corticosteroids and immune globulins count once each.

The exact cause of Sjögren's Syndrome is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. No confirmed causative gene; autoimmune predisposition runs in families without a defined inheritance pattern. Estimated 1 to 4 million Americans (including undiagnosed); approximately 1 in 1,000 adults based on physician-diagnosed prevalence. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Sjögren's Syndrome. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. No confirmed causative gene; autoimmune predisposition runs in families without a defined inheritance pattern.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Sjögren's Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Sjögren's Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.